Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5557408 | 0.91 | TK2 (0.42) | TK2TK1 | |
| SCHEMBL24512779 | 0.91 | TK2 (0.42) | TK2TK1 | |
| SCHEMBL2769235 | 0.91 | TK2 (0.42) | TK2TK1 | |
| SCHEMBL5582060 | 0.91 | TK2 (0.42) | TK2TK1 | |
| SCHEMBL25630027 | 0.88 | TK2 (0.40) | TK2TK1 | |
| SCHEMBL5558232 | 0.88 | TK2 (0.40) | TK2TK1 | |
| SCHEMBL2770802 | 0.88 | TK2 (0.40) | TK2TK1 | |
| SCHEMBL24512780 | 0.86 | TK2 (0.38) | TK2TK1 | |
| SCHEMBL3841357 | 0.85 | TK2 (0.40) | TK2TK1 | |
| SCHEMBL19305222 | 0.85 | TK2 (0.41) | TK2TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1201678-B1 | NOVEL BICYCLONUCLEOSIDE ANALOGUES | SANKYO CO (JP) | 2004-09-22 | — | — | EP | claimed |
| EP-1201678-A1 | NOVEL BICYCLONUCLEOSIDE ANALOGUES | Sankyo Company, Limited (JP) | 2002-05-02 | — | — | EP | claimed |
| US-7994145-B2 | Bicyclonucleoside analogues | TAKESHI IMANISHI (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20070270370-A1 | Novel bicyclonucleoside analogues | SANKYO COMPANY, LIMITED (JP) | 2007-11-22 | — | — | US | disclosed |
| US-7217805-B2 | Bicyclonucleoside analogues | SANKYO COMPANY, LIMITED (JP) | 2007-05-15 | — | — | US | disclosed |
| EP-1201678-B1 | NOVEL BICYCLONUCLEOSIDE ANALOGUES | SANKYO CO (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-20040143114-A1 | Novel bicyclonucleoside analogues | SANKYO COMPANY, LIMITED (JP) | 2004-07-22 | — | — | US | disclosed |
| EP-1201678-A1 | NOVEL BICYCLONUCLEOSIDE ANALOGUES | Sankyo Company, Limited (JP) | 2002-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270370-A1 | Novel bicyclonucleoside analogues | PURB, RNGTT, NSUN2 | TK2 231/4885TK1 133/4885 |
| US-20040143114-A1 | Novel bicyclonucleoside analogues | PURB, DUT, NSUN2 | TK2 205/4885TK1 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.